Capital Advisors Inc. OK Buys 8,229 Shares of Stryker Corporation $SYK

Capital Advisors Inc. OK grew its stake in shares of Stryker Corporation (NYSE:SYK) by 5.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 172,517 shares of the medical technology company’s stock after purchasing an additional 8,229 shares during the period. Capital Advisors Inc. OK’s holdings in Stryker were worth $60,635,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in SYK. Lodestone Wealth Management LLC bought a new position in Stryker in the fourth quarter worth approximately $66,000. BTC Capital Management Inc. grew its stake in Stryker by 19.6% in the fourth quarter. BTC Capital Management Inc. now owns 2,815 shares of the medical technology company’s stock valued at $989,000 after acquiring an additional 462 shares during the period. DB Fitzpatrick & Co Inc increased its holdings in shares of Stryker by 21.3% during the fourth quarter. DB Fitzpatrick & Co Inc now owns 4,136 shares of the medical technology company’s stock valued at $1,454,000 after acquiring an additional 726 shares in the last quarter. Nikulski Financial Inc. raised its position in shares of Stryker by 112.8% during the fourth quarter. Nikulski Financial Inc. now owns 7,113 shares of the medical technology company’s stock worth $2,500,000 after purchasing an additional 3,770 shares during the period. Finally, Fifth Third Wealth Advisors LLC raised its position in shares of Stryker by 3.9% during the fourth quarter. Fifth Third Wealth Advisors LLC now owns 7,161 shares of the medical technology company’s stock worth $2,517,000 after purchasing an additional 271 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 0.7%

SYK stock opened at $328.34 on Wednesday. The firm has a market capitalization of $125.75 billion, a PE ratio of 39.09, a P/E/G ratio of 1.91 and a beta of 0.85. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. Stryker Corporation has a twelve month low of $319.32 and a twelve month high of $404.87. The stock’s 50 day moving average is $358.77 and its 200-day moving average is $362.73.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.40 by $0.07. The business had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. Stryker had a return on equity of 24.41% and a net margin of 12.92%.Stryker’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.01 earnings per share. Sell-side analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be paid a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio is presently 41.90%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. UBS Group reduced their price target on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research report on Tuesday, March 17th. Evercore set a $390.00 price objective on shares of Stryker in a report on Monday, January 5th. Needham & Company LLC raised their price objective on shares of Stryker from $448.00 to $454.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $465.00 price objective on shares of Stryker in a research note on Wednesday, March 4th. Finally, Citigroup reiterated a “market outperform” rating on shares of Stryker in a report on Friday, January 30th. Fourteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average price target of $427.50.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director directly owned 2,457,331 shares of the company’s stock, valued at $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.20% of the stock is currently owned by corporate insiders.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.